
Campbell Tiley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4461291/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 2012, 120, 1570-1580.	1.4	268
2	Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematology,the, 2015, 2, e357-e366.	4.6	133
3	Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 2010, 69, 484-497.	2.4	66
4	High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. British Journal of Clinical Pharmacology, 2016, 82, 149-159.	2.4	43
5	A multi-center randomized controlled trial to reduce unmet needs, depression, and anxiety among hematological cancer patients and their support persons. Journal of Psychosocial Oncology, 2020, 38, 272-292.	1.2	20
6	ldarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. Journal of Clinical Oncology, 2017, 35, 1678-1685.	1.6	14
7	â€~Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma. Leukemia and Lymphoma, 2018, 59, 1514-1516.	1.3	11
8	A phase <scp>II</scp> study of riskâ€edapted intravenous melphalan in patients with <scp>AL</scp> amyloidosis. British Journal of Haematology, 2012, 157, 766-769.	2.5	9
9	Lymphoma cellâ€of–origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts. British Journal of Haematology, 2018, 181, 272-275.	2.5	8
10	The delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complications. Pathology, 2018, 50, 775-776.	0.6	6
11	Australia and New Zealand Transplant and Cellular Therapies <scp>COVIDâ€19</scp> vaccination consensus position statement. Internal Medicine Journal, 2021, 51, 1321-1323.	0.8	6
12	A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood, 2012, 120, 436-436.	1.4	6
13	Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies. Experimental Hematology and Oncology, 2015, 4, 15.	5.0	4
14	Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 11-12.	1.4	2
15	A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,. Blood, 2011, 118, 3973-3973.	1.4	1
16	Promising Real World Survival Data in Adult-Onset Langerhans Cell Histiocytosis: An Australasian Lymphoma Alliance 20 Year Retrospective Study. Blood, 2021, 138, 2570-2570.	1.4	1
17	Lower Drug Exposure Is Related to Renal Function and Results in Inferior Survival: A Pharmacokinetic Study of High Dose Melphalan in Myeloma. Blood, 2012, 120, 1979-1979.	1.4	0
18	Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study. Blood, 2019, 134, 4150-4150.	1.4	0

#	Article	IF	CITATIONS
19	In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial. Blood, 2019, 134, 4247-4247.	1.4	0